The article highlights the potentially game-changing approach of the Company towards treating Alzheimer’s Disease, based on technology developed at Rutgers by Dr. Luciano D’Adamio, PhD, MD, New Jersey ...

antibody- or complement-dependent cell-mediated cytotoxicity; and reverse signaling through ligation with transmembrane TNF. By blocking TNF, these agents may lead to serious adverse affects.

(In justifying to Centocor why it would be wise to invest in the development of antibodies to lymphotoxin and TNF, I mentioned the possibility of their therapeutic usefulness in autoimmune diseases.) ...

Tumor necrosis factor (TNF)-alpha, a proinflammatory cytokine, has been implicated in the pathogenesis of AD. Objective: To investigate the use of a biologic TNF-alpha inhibitor, etanercept was ...

Sino Biological offers a comprehensive selection of recombinant TNF and TNFR proteins and corresponding antibodies that support drug discovery and development research on TNFs/TNFRs. TNFRSF ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...